The virtual automotive artist behind the "Evren Ozgun Spy Sketch" channel on YouTube has a 'slightly' different ...

This virtual artist, better known as "Theottle" on social media, has resorted to CGI slicing and dicing his proposed new iteration of the Toyota Sienna minivan ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...

Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $533.00. The company’s shares closed ...

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Talk about wealth-generating powerhouses — a handful of S&P 500 companies now pull in at least $10,000 a second in revenue.

Showcase your company news with guaranteed exposure both in print and online 25 years ago, Denver's economy thrived on IT, real estate & oil. DBJ will kick… Be Inspired! Meet Your Mentor! Make ...